Purpose: To assess the antitumor efficacy and safety of a vinorelbine and cisplatin combination in patients with metastatic breast cancer previously treated with anthracyclines.
Introduction
First-line combination chemotherapy for metastatic breast cancer with regimens including anthracyclines (CAF, CEF, etc.) induces an objective response in 50%-80% of patients [1] [2] [3] [4] but the median duration of response is usually less than one year. After failure or progression with these regimens, responses are harder to obtain with subsequent regimens. Increasing use of anthracyclines in adjuvant treatment has also led to a limitation of their use in relapsed patients. The need has therefore emerged for non-anthracycline-containing regimens for the treatment of those relapsed patients. Docetaxel [5] [6] [7] [8] and paclitaxel [9] [10] [11] [12] are highly active agents for metastatic breast cancer and have demonstrated activity in anthracycline-resistant patients and are often used alone or in combination with other drugs as first-or second-line chemotherapy. However, the use of taxanes is limited in most countries because of their high cost. Therefore, the need for salvage regimens with other drugs remains highly important in advanced breast cancer.
Vinorelbine (VNR; Navelbine, Pierre Fabre Medicant, Boulogne, France) is a semisynthetic vinca alkaloid which differs from vinblastine by a substitution that affects the catharanthine moiety and not the vindoline moiety of the molecule. Neurotoxicity was not observed in animal models. In humans VNR is associated with only mild non-haematological toxicity and minor neurotoxic effects. The highly selective affinity of VNR for mitotic rather than axonal tubulin may account for this finding [13, 14] . In first-line therapy for advanced breast cancer response rates were observed in four large phase II studies range from 41%-50% (mean 45%) [15] [16] [17] [18] . Cisplatin as a single agent in first-line therapy for metastatic breast cancer is also effective with response rates of 47%-54% [19, 20] . In combination with docetaxel, cisplatin indicates a high response in patients pretreated with anthracyclines [21] . However, its activity in combination with other drugs is not yet well known. VNR has synergistic antitumoral activity with cisplatin in animal models [22] . Acceptable tolerance has been observed when the two drugs were used in combination in pretreated breast cancer patients [23] .
One published study suggests that an intensive fiveday regimen with cisplatin 20 mg/m 2 and VNR 6 mg/m 2 in continuous i.v. infusion over five days may induce a high response rate with an objective response at 41% (95% CI: 28-54) after failure of anthracyclines including polychemotherapy [23] . However, the use of this regimen is restricted in daily clinical practice as it requires hospitalization of the patients treated. Based on these data we combined cisplatin 75 mg/m 2 given on day 1 and VNR 25 mg/m 2 given on days 1 and 8 in the day clinic and performed a study in the unfavourable set of metastatic breast cancer patients who failed with at least one anthracycline-containing regimen.
Patients and methods

Patients
Patients aged between 28 and 73 years with a confirmed diagnosis of breast cancer who had relapsed after previous exposure to adjuvant or palliative chemotherapy regimens with anthracyclines were eligible.
It is required that all patients had measurable disease, with defined index lesions > 1 cm in size on physical examination, X-ray, ultrasound or CT scan. Any prior hormonal therapy should have discontinued at least four weeks before protocol therapy. Patients had to have received at least one anthracycline-based regimen previously. In addition, patients were classified according to their anthracycline-resistance as:
• Anthracycline refractory patients: those who have never responded under anthracycline therapy.
• Anthracycline resistant patients: metastatic patients who have progressed under anthracycline combination or within four months of the end of an anthracycline regimen or within six months of completion of an anthracycline adjuvant treatment.
• Previously treated with anthracyclines or relapsed patients:
those who have progressed four months after the end of an anthracycline regimen in metastatic setting or six months after the end of an anthracycline regimen in adjuvant setting. The need for active treatment was mandatory not only for good PS patients but for patients with more advanced disease status as well: we included, therefore, patients with PS up to 3 in the study.
Other eligibility criteria for entry into the study were an expected survival ^ 3 months, pretreatment adequate haematological parameters (white blood counts S=3500/dl. platelet count 5100.000/dl and hemoglobin 5=11 g/dl), creatinine < 1.5 mg/dl. creatinine clearancê 60 ml/min (creatinine clearance was calculated upon 24 hrs urine creatinine secretion according to the formula: mg/ml urine x ml urine/ml/mg/ml plasma) and bilirubin <2 mg/dl. An informed consent was obtained from all patients, and the study was approved by the ethics committee of St Savas Hospital.
Methods
Treatment consisted of cisplatin administered intravenously over one hour at the dose of 75 mg/m 2 on day 1 of the cycle. Adequate pre-and post-hydration was given. VNR administered at the dose of 25 mg/m 2 in 50 ml of normal saline (NS) over 5-10 min followed by a 200 ml NS bolus to prevent phlebitis, on days 1 and 8. Antiemetic therapy by 5-HT3 antagonists was applied in all cases. Vigorous hydration, 2000 ml NS with K.C1, was given over four hours prior to cisplatin. Furosemide 40 mg i.v. 20 min. prior to cisplatin was also given. Hydration with 1000 ml D5Wand 1000 ml NS followed cisplatin infusion for four hours. Urinary output was followed during this time. Treatment was given under continuous supervision in the day clinic. All patients were instructed to drink fluids when discharged and to measure urinary output as well. The regimen was repeated every three weeks until evidence of disease progression and for a maximum of six courses.
All eligible patients were evaluated for response and toxicity which were recorded according to the WHO criteria [24] . For bone lesions, a CR required complete recalcification of all lytic lesions on X-ray or CT scan. Venous local tolerance was assessed according to Rittenberg et al. [25] scale for venous irritation. Toxicity monitoring included complete blood counts (CBC) with differential and platelets on days 8, 15 and 21 of every cycle. When a grade 3 or 4 hematologic toxicity was reported, CBC counts were performed biweekly until recovery. The VNR dose on day 8 was given only in the presence of an absolute neutrophil count (ANC) > 1500/dl and platelets count > 100000/dl. When grade 3 or 4 neutropenia occurred granulocyte colony-stimulating factor (G-CSF) 3 ug/kg SC on days 3-6 and 9-15 was given for all treatment cycles afterwards. Dose reduction of VNR by 50% was performed in case of febrile neutropenia and 25% reduction was performed in case of persistent grade 3 and 4 neutropenia existed after G-CSF secondary prophylaxis.
Before each cycle, serum creatinine, creatinine clearance and serum electrolytes including magnesium, were performed. If the serum creatinine was 1.5-2 mg/dl, but creatinine clearance was > 50ml/min, the cisplatin dose was reduced by 25%. Cisplatin was stopped if the clearance was less than 50 ml/min. No dose reduction for cisplatin was allowed due to myeolotoxicity.
Patients who received at least one course were considered assessable for response. Tumor measurements were performed every two cycles Duration of response was measured from the onset of best response. Effusions and osteoblastic lesions were not regarded as objectively measurable. Patients were evaluated for antitumor activity (WHO criteria) and time-related parameters. Time to progression (TTP) and overall survival (OS) were calculated from the date of entry into the study until disease progression or death using the KaplanMeier product-limit method. Response rates were recorded using Pearson chi-square (x 2 ) and binomial test.
Results
Response to therapy
Fifty-three patients entered the study and were all assessable for response and toxicity. Patient characteristics are given in Table 1 . The median age of the patients was 50 years (range 28-73). Thirty patients were premenopausal and twenty-three postmenopausal. Seventeen patients (32%) had stage-IV disease at initial diagnosis. The median time elapsed from primary diagnosis to progress was 12 months (range 1-55), and to study entry 18 months (range 6-60). Bone was the most affected site (51%), followed by liver (47%), lung (38%), chest wall/ skin (32%), lymph nodes (25%), breast (17%) and pleural effusion (13%). Eleven patients had one tumoral site (38) 17 (32) 13 (25) 9 (17) 7 (13) 3 (6) 11(21) 20 (38) 22 (41) n (%) (21%), twenty had two (38%) and twenty-two (41%) had three or more. Prior systemic therapy is listed in Table 2 . Twenty-five patients (47%) had previously received hormonal therapy. All patients had failed with anthracyclines either in adjuvant (6 patients) or palliative setting (47 patients). Thirty-two patients (68%) had previously received one chemotherapy regimen for metastatic disease, thirteen (28%) had received two regimens and two (4%) three regimens. Three patients had also received high-dose chemotherapy which had failed.
Response data to cisplatin-VNR are shown in Table 3 . Twenty-two of fifty-three evaluable patients had a PR (41%) and four patients (8%) had a CR, giving an ORR of 49% (95% Cl: 35-63). Stable disease was observed in five patients (9%). Response according to previous chemotherapy is also given in Table 3 . Anthracycline refractory patients: 5 patients achieved a PR (36%) and no patient achieved a CR (0%), for a total of 5 responses (36%) from 14 patients. Anthracycline resistant patients: 6 patients achieved a PR (38%) and 1 achieved a CR (6%), for a total of 7 responses (44%) from 16 patients. Anthracycline relapsed patients: 11 patients achieved a PR (48%) and 3 achieved a CR (13%), for a total of 14 responses (61%) from 23 patients.
The median duration of response was seven months (range 3-14) and the median time to response was six weeks (range 3-12). The median TTP was five months (range 1-16, Figure 1 ). The median survival time from entry into study was 12 months (Figure 2 ) and from diagnosis of metastatic disease 27 months ( Figure 3) . Responses according to patients' tumor sites are shown in Table 4 . The objective responses reported according to site of metastasis were lung 11 of 20 (55%), liver 11 of 25 (44%), bone 11 of 27 (41%), chest wall/skin 10 of 17 (59%), lymph nodes 6 of 13 (46%). According to the number of involved target sites the response rate was as follows: one site 64%, two sites 55%, > three 36%. Two CRs obtained in visceral (lung), one in bone and eight in soft tissue metastatic disease. There is no statistically significant difference among the response rates of tumor sites {P = 0.91) and the number of metastatic sites (/> = 0.268), respectively.
Treatment and tolerance
Two hundred twenty-eight courses were administered. The mean number of treatments with the combination 2 (4) 26 (49) 5 (9) 5 (9) 0(0) 0(0) 1 (2) 1 (2) 1 (2) a Toxicity according to Rittenberg et al. criteria. was 4.0 per patient (range 1-6). Doses of VNR and or cisplatin were reduced in 38 cycles (17%) by 25%. VNR was reduced in nine patients and cisplatin in three patients. For cisplatin the mean dose-intensity was 0.95 (range 0.76-1.0). For VNR the mean dose per injection was 23 mg/m 2 and the mean dose-intensity was 0.92 (range 0.8-1.0).
Toxicity was largely haematopoietic (Table 5 ). Only two patients were admitted for infection and required i.v. antibiotics. Twenty-six patients (49%) showed grade 3 or 4 neutropenia and five patients (9%) showed grade 3 or 4 thrombocytopenia (2 of them needed platelet transfusion). Two of them had bone marrow infiltration by tumor cells and one had folinic-acid deficiency that is with serum level below 3 ng/ml. G-CSF was administered in 26 patients because of neutropenia. Anemia was rare (2 of patients with grade 3; 4%). Non-hematological toxicity is also listed in Table 4 . Mild nausea and vomiting occurred in the majority of patients; only five patients (9%) showed grade 3 toxicity. Peripheral neuropathy was also mild in eight cases and completely reversible. Grade 1 and 2 nephrotoxicity occurred in four patients. Chemical phlebitis at the infusion site (grade 1-3 by Rittenberg et al. scale) was seen in 11 patients. Six patients experienced orthostatic hypotension (1 patient with grade 3; 2%), and eight patients showed asthenia of two weeks duration after cisplatin administration. No toxic deaths occurred.
Discussion
In this study we report the efficacy of cisplatin-VNR regimen in metastatic breast-cancer patients pretreated with anthracycline chemotherapy. Failed patients to anthracyclines have a poor prognosis [26] [27] [28] and response rates of 21% have been reported [29, 30] . Of the new agents investigated in recent years, taxanes seem to show promising results in this group of patients. In phase II studies response rates ranging from 29% to 50% and 22% to 42% were documented with docetaxel [5, 6, 31, 32] and paclitaxel [11, 12, 33, 34] , respectively. However, the high cost of taxanes prohibits their worldwide use and a search for alternative second and thirdline salvage regimens is mandatory.
Cisplatin as first-line single agent chemotherapy results in an ORR approaching 50% [19] . In heavily pretreated refractory patients response ranges from 6% to 21% [35, 36] . VNR had an established activity as single agent for metastatic breast cancer either as first-line or secondline treatment with response rates 41%-50% [15, 16] and 30% [37] , respectively. Synergistic antitumoral activity of cisplatin and VNR has been observed in animal models [22] . The combination was tested with acceptable toxicity in lung [38] and cervical cancer [39] patients.
The encouraging results with VNR as a single agent in phase II studies [40, 41] in stage IV breast cancer and the synergistic activity of the drug with cisplatin as well as the paucity of non-taxane combinations for treatment after anthracycline failure prompted us to investigate the activity of these agents in anthracycline-exposed and progressing patients.
In our study we treated 53 metastatic breast-cancer patients exposed to anthracyclines and previous treatment to one, two or three chemotherapeutic regimens, a selected population with an unfavourable outcome. An ORR of 49% achieved indicates that cisplatin-VNR is an effective regimen for such patients. This compares favorably with 20%-25% response rate achieved with various regimens used in anthracycline-resistant breast cancer [29, 30] and is similar to the response obtained with a more intensified regimen with cisplatin 20 mg/m 2 /day in combination with VNR 6 mg/m 2 /day in continuous infusion over five days [23] . ORR in this trial with 58 patients was 41% (95% CI: 28-54) with 3% complete responders and 38% partial responders. A high response rate was also achieved with 7 of 12 patients who were previously treated with paclitaxel and anthracyclines. In another report with cisplatin 90 mg/m 2 given over three days and VNR 25 mg/m 2 on days 1, 8, and 15, 5 of 12 patients (42%) pretreated with anthracyclines responded [42] .
We further analyzed our data according to chemosensitivity to anthracyclines in an attempt to determine predictive factors for response. Each subgroup was analyzed separately for its response to cisplatin-VNR. Anthracycline refractory and resistant patients had a lower ORR (36% and 44% respectively) when compared with relapsed patients (61%). However, this difference was not statistically significant. Complete responses occurred mainly in relapsed patients (13%). These findings suggest that anthracycline-pretreated patients constitute a heterogeneous group in terms of sensitivity to cisplatin-VNR. This behaviour has also been observed when docetaxel was given to anthracycline-pretreated patients [7] . Recently, a randomized trial of docetaxel versus mitomycin-C-vinblastine showed superiority of docetaxel in terms of response (30% vs. 11.6%), TTP (19 vs. 11 weeks) and survival (11.4 vs. 8.7 months) [8] . However, the combination of cisplatin-docetaxel in anthracycline-failing patients had moderate activity with ORR 36%, median TTP 21 weeks and OS 50 weeks [17] . The median-survival time from the initiation of our study was 12 months and median TTP 5 months.
Although our data suggest that cisplatin-VNR offers results similar to taxanes alone or in combination with other drugs [43] , randomized studies are necessary for comparison of the activity and toxicity of these regimens. The cisplatin-VNR combination independent of its activity and cost effectiveness requires hydration and may be less convenient for the patients.
It is interesting that cisplatin-VNR was shown to have major activity at all sites of disease including skeletal and visceral metastases. The response rate was influenced by the number of metastatic sites as patients with less than two metastatic sites responded better than patients who had three or more.
The profile of hematological and non-hematological toxicity was moderate and manageable. Granulocytopenia (grade 3 and 4) was observed in 49% of patients with only 2 infections requiring hospitalization. Despite the potential neurotoxicity of both drugs, neurosensory toxicity was low and occurred in only 15% of the patients (grade 1 and 2). The cisplatin-VNR combination appears to be less toxic than cisplatin-docetaxel in anthracycline-failing patients [21] ; 93% of patients treated with ciplatin-docctaxcl showed severe neutropenia with 29% of patients being febrile; among these patients there was one death due to septic shock.
As responses with cisplatin-VNR with doses given in our study are similar to higher doses [23] and suggest non-cross resistance to anthracyclines, we believe that this combination can be used as an efficient salvage regimen in anthracycline failures and needs randomized studies for comparison of the activity of our regimen with taxane regimens.
